ANDRÉS JESÚS
MUÑOZ MARTÍN
Profesor asociado
Hospital Universitario Puerta del Mar
Cádiz, EspañaPublications in collaboration with researchers from Hospital Universitario Puerta del Mar (7)
2021
-
Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study
Cancers, Vol. 13, Núm. 18
-
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients
Annals of Hematology, Vol. 100, Núm. 4, pp. 1023-1029
2018
2015
-
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: The phase II AVAXIRI study
BMC Cancer, Vol. 15, Núm. 1
-
Erratum: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study [Support Care Cancer, DOI 10.1007/s00520-015-2809-3]
Supportive Care in Cancer
-
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Supportive Care in Cancer, Vol. 23, Núm. 9, pp. 2833-2840
2007
-
Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease
Haematologica, Vol. 92, Núm. 11, pp. 1489-1494